Mereo BioPharma Group plc - American Depositary Shares (MREO)
MREO moved a median of +0.25% 30 minutes after news, and +0.23% by the close. How MREO actually reacts to news — the realized, point-in-time move the market made, measured across 750 labeled events over the last three years with zero look-ahead.
MREO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.02% | 52% | 745 |
| 30-min | +0.25% | 55% | 748 |
| 60-min | +0.42% | 54% | 748 |
| to close | +0.23% | 51% | 741 |
| Middle 50% of MREO reactions | -1.65% to +2.07% |
|---|---|
| Median reaction (30-min) | +0.25% |
| Measured reactions | 750 |
Half of all Mereo BioPharma Group plc - American Depositary Shares news events land between -1.65% and +2.07% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MREO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 12 | +4.64% | 67% | +8.92% |
| Coverage initiations | 12 | +1.39% | 75% | +1.45% |
| Rating reiterations | 51 | +0.13% | 53% | +1.55% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how MREO ranks against every other measured name →
That’s how MREO usually reacts — get an email when it moves on news →Email me when MREO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MREO's baseline. Nothing else.
Recent MREO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Mereo BioPharma Group For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +6.66% | +8.92% | |
| Form 10-Q Mereo BioPharma Group For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -9.04% | -16.32% | |
| Form 8-K Mereo BioPharma Group For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -9.04% | -16.32% | |
| Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) | Press release | GlobeNewswire | -9.04% | -16.32% | |
| Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights | Press release | GlobeNewswire | -9.04% | -16.32% | |
| Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) | Press release | PR Newswire | -9.04% | -16.32% | |
| 4basebio Announces Appointment of Chief Financial Officer and Board Changes | Press release | GlobeNewswire | +2.58% | -5.38% | |
| Form 8-K Mereo BioPharma Group For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +1.45% | -3.64% | |
| Form 10-Q Mereo BioPharma Group For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.16% | +0.41% | |
| Form 8-K Mereo BioPharma Group For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +2.16% | +0.41% | |
| Form 8-K/A Mereo BioPharma Group For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +2.16% | +0.41% | |
| Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | Press release | GlobeNewswire | +2.16% | +0.41% | |
| Form ARS Mereo BioPharma Group For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.06% | +0.16% | |
| Form DEF 14A Mereo BioPharma Group For: Apr 08 | SEC filing · Form DEF | SEC EDGAR | -0.06% | +0.16% | |
| Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO | Press release | PR Newswire | -0.22% | -2.17% | |
| Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO | Press release | PR Newswire | -0.92% | -2.77% | |
| Form 8-K Mereo BioPharma Group For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | -2.05% | |
| Form PRE 14A Mereo BioPharma Group For: Mar 27 | SEC filing · Form PRE | SEC EDGAR | -0.69% | -2.05% | |
| Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO | Press release | PR Newswire | +3.94% | +3.82% | |
| Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO | Press release | PR Newswire | +1.84% | -1.70% | |
| Form 10-K Mereo BioPharma Group For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -7.14% | +3.06% | |
| Form 8-K Mereo BioPharma Group For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | -7.14% | +3.06% | |
| Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights | Press release | GlobeNewswire | -7.14% | +3.06% | |
| Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO | Press release | PR Newswire | +0.00% | -0.80% | |
| Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO | Press release | PR Newswire | +3.34% | +13.51% | |
| Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO | Press release | PR Newswire | -0.32% | -1.54% | |
| Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately | Press release | PR Newswire | +4.55% | +5.37% | |
| Form 8-K Mereo BioPharma Group For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +1.85% | +2.68% | |
| Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately | Press release | PR Newswire | -5.22% | +11.24% | |
| Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately | Press release | GlobeNewswire | +1.02% | -3.64% | |
| Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO | Press release | PR Newswire | -5.20% | -4.20% | |
| Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MREO | Press release | Business Wire | +3.15% | +13.96% | |
| Form S-8 Mereo BioPharma Group | SEC filing · Form S-8 | SEC EDGAR | +1.09% | -6.46% | |
| TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight | Press release | PR Newswire | +1.09% | -6.46% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.20% | +4.71% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.59% | -4.06% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -1.70% | +14.52% | |
| Form 8-K Mereo BioPharma Group For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | +0.23% | |
| Mereo BioPharma Provides Corporate Update | Press release | GlobeNewswire | +0.29% | +0.23% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.29% | +0.23% | |
| Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.56% | -2.63% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.79% | -6.95% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -1.08% | -5.86% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mereo BioPharma Group plc (MREO) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.60% | +15.99% | |
| Form 8-K Mereo BioPharma Group For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | -12.40% | +14.16% | |
| Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta | Press release | GlobeNewswire | -12.40% | +14.16% | |
| Form 10-Q Mereo BioPharma Group For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.12% | +4.47% | |
| Form 8-K Mereo BioPharma Group For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +1.12% | +4.47% | |
| Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights | Press release | GlobeNewswire | +1.12% | +4.47% | |
| Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight | Press release | PR Newswire | +0.47% | -2.34% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MREO section they belong to.
Where else MREO is measured.
MREO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Mereo BioPharma Group plc - American Depositary Shares's median reaction calculated?
Every labeled MREO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 750 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of MREO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MREO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.